Skip to main content
. Author manuscript; available in PMC: 2022 Dec 16.
Published in final edited form as: N Engl J Med. 2022 Jun 4;386(24):2261–2272. doi: 10.1056/NEJMoa2200075

Figure 1. Receipt of Adjuvant Chemotherapy in the Intention-to-Treat Population According to Subgroup.

Figure 1.

The relative risk and 95% confidence intervals for the receipt of adjuvant chemotherapy in the standard-management group as compared with the circulating tumor DNA (ctDNA)–guided group are shown. The intention-to-treat population included all eligible patients who underwent randomization and had both week 4 and week 7 postsurgical blood specimens. The size of each square corresponds to the size of the subgroup. For the subgroup with poorly differentiated tumors, the relative risk lies beyond the upper limit of the horizontal axis and is not shown.